Gradient Investments Has Cut Its Progenics Pharmaceuticals In (PGNX) Holding; Templeton Global Income Fund (GIM)’s Sentiment Is 1.24

June 12, 2018 - By mmahotstuff

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Logo

Gradient Investments Llc decreased Progenics Pharmaceuticals In (PGNX) stake by 93.19% reported in 2018Q1 SEC filing. Gradient Investments Llc sold 69,138 shares as Progenics Pharmaceuticals In (PGNX)’s stock rose 15.51%. The Gradient Investments Llc holds 5,054 shares with $38,000 value, down from 74,192 last quarter. Progenics Pharmaceuticals In now has $647.99M valuation. The stock increased 0.69% or $0.06 during the last trading session, reaching $8.79. About 956,127 shares traded. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) has risen 11.08% since June 12, 2017 and is uptrending. It has underperformed by 1.49% the S&P500. Some Historical PGNX News: ; 19/03/2018 – Progenics Pharmaceuticals Announces Presentation of AZEDRA® (iobenguane I 131) Biochemical Tumor Marker Data at the 2018 Endoc; 11/05/2018 – PROGENICS PHARMA-ON MAY 10, CO, VALEANT, AMONG OTHERS & PAR STERILE PRODUCTS, PAR PHARMA ENTERED SETTLEMENT AGREEMENT RELATING TO PATENT INFRINGEMENT; 15/05/2018 – Armistice Capital Buys New 3.3% Position in Progenics; 02/04/2018 – Progenics Presenting at Conference Apr 9; 02/05/2018 – Summary Judgment Granted Upholding the Validity of Formulation Patent Protecting RELISTOR® Injection; 16/05/2018 – Progenics Closes Above 50-Day Moving Average: Technicals; 09/05/2018 – Progenics Pharmaceuticals 1Q-End Cash and Cash Equivalents $83.4M; 19/03/2018 – Progenics Pharmaceuticals Announces Presentation of AZEDRA® (iobenguane l 131) Biochemical Tumor Marker Data at the 2018 Endocrine Society (ENDO) Annual Meeting; 15/05/2018 – Progenics Pharmaceuticals: Elucidating The Upcoming Regulatory Binary For Azedra; 22/05/2018 – Progenics Announces JAMA Oncology Publication Highlighting Company’s Imaging Analysis Platform

Templeton Global Income Fund (GIM) investors sentiment increased to 1.24 in Q1 2018. It’s up 0.14, from 1.1 in 2017Q4. The ratio has increased, as 47 hedge funds started new and increased stock positions, while 38 reduced and sold their holdings in Templeton Global Income Fund. The hedge funds in our database now possess: 32.54 million shares, up from 29.92 million shares in 2017Q4. Also, the number of hedge funds holding Templeton Global Income Fund in top ten stock positions increased from 0 to 2 for an increase of 2. Sold All: 16 Reduced: 22 Increased: 33 New Position: 14.

Among 5 analysts covering Progenics Pharm (NASDAQ:PGNX), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Progenics Pharm has $15 highest and $9 lowest target. $13.75’s average target is 56.43% above currents $8.79 stock price. Progenics Pharm had 11 analyst reports since August 6, 2015 according to SRatingsIntel. The stock of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) has “Buy” rating given on Tuesday, June 20 by Needham. Aegis Capital initiated Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) on Thursday, October 27 with “Buy” rating. Brean Capital maintained Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) on Thursday, August 6 with “Buy” rating. As per Tuesday, September 26, the company rating was maintained by Jefferies. On Monday, February 6 the stock rating was upgraded by Needham to “Strong Buy”. The rating was maintained by Jefferies with “Buy” on Thursday, June 8. The company was maintained on Wednesday, August 9 by Cantor Fitzgerald. As per Friday, October 23, the company rating was upgraded by Jefferies. The stock has “Buy” rating by Zacks on Friday, August 7. On Friday, August 7 the stock rating was maintained by Needham with “Buy”.

Investors sentiment increased to 1.31 in Q1 2018. Its up 0.09, from 1.22 in 2017Q4. It increased, as 18 investors sold PGNX shares while 34 reduced holdings. 20 funds opened positions while 48 raised stakes. 59.46 million shares or 4.52% more from 56.89 million shares in 2017Q4 were reported. Prudential Finance, New Jersey-based fund reported 114,362 shares. Envestnet Asset Mngmt owns 3,614 shares or 0% of their US portfolio. Profund Limited Company stated it has 0% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Atlantic Tru Gp Lc invested in 2,683 shares. Duncker Streett Communications holds 0.03% or 15,718 shares. New York State Teachers Retirement Sys has invested 0% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Fmr Lc reported 1.47M shares. Fifth Third Fincl Bank holds 0% of its portfolio in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) for 10,300 shares. Opus Point Mgmt Lc accumulated 10,891 shares. Horizon Kinetics Ltd Liability has 67,200 shares for 0.01% of their portfolio. Moreover, Geode Mngmt Ltd Liability has 0% invested in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Wells Fargo & Mn accumulated 180,757 shares. Daiwa Secs reported 388 shares stake. Westwood Mngmt Corporation Il holds 12,000 shares. Parallax Volatility Advisers LP accumulated 0% or 1,959 shares.

Gradient Investments Llc increased Powershares Etf Tr Ii (EEHB) stake by 2.04 million shares to 21.15 million valued at $441.31M in 2018Q1. It also upped Philip Morris Intl Inc (NYSE:PM) stake by 4,265 shares and now owns 87,112 shares. Ishares Tr (SHYG) was raised too.

Analysts await Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) to report earnings on August, 8. They expect $-0.18 EPS, up 25.00% or $0.06 from last year’s $-0.24 per share. After $-0.19 actual EPS reported by Progenics Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -5.26% EPS growth.

More important recent Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) news were published by: Globenewswire.com which released: “Progenics Announces JAMA Oncology Publication Highlighting Company’s Imaging Analysis Platform” on May 22, 2018, also Seekingalpha.com published article titled: “Progenics: What Is The Value Of The Imaging Pipeline?”, Nasdaq.com published: “Amicus Therapeutics Appoints President and COO Bradley L. Campbell to Board of Directors” on June 08, 2018. More interesting news about Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) was released by: Seekingalpha.com and their article: “Progenics Pharmaceuticals: Elucidating The Upcoming Regulatory Binary For Azedra” with publication date: May 21, 2018.

Jnba Financial Advisors holds 11.33% of its portfolio in Templeton Global Income Fund for 1.02 million shares. Financial & Investment Management Group Ltd owns 1.18 million shares or 2.43% of their US portfolio. Moreover, Pekin Singer Strauss Asset Management Il has 2.12% invested in the company for 1.80 million shares. The Illinois-based Rivernorth Capital Management Llc has invested 2.07% in the stock. Windsor Capital Management Llc, a Arizona-based fund reported 561,524 shares.

Another recent and important Templeton Global Income Fund (NYSE:GIM) news was published by Globenewswire.com which published an article titled: “Templeton Global Income Fund (“GIM”) Announces Distribution” on June 01, 2018.

The stock increased 0.16% or $0.01 during the last trading session, reaching $6.19. About 296,958 shares traded or 10.10% up from the average. Templeton Global Income Fund (GIM) has declined 5.31% since June 12, 2017 and is downtrending. It has underperformed by 17.88% the S&P500.

Since January 1, 0001, it had 1 buying transaction, and 0 sales for $49,959 activity.

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>